Blog
RSS FeedPosted by Michael Wonder on 12 Mar 2019
SMC says ‘no’ to Novartis’ Kymriah for adults with lymphoma
11 March 2019 - Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS ...
Posted by Michael Wonder on 21 Feb 2019
Japan approves two gene treatments in bid to catch up
21 February 2019 - Potential revolutionary treatments have exorbitant price tags. ...
Posted by Michael Wonder on 20 Feb 2019
Gilead receives approval in Canada for Yescarta (axicabtagene ciloleucel) CAR T therapy for adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy
19 February 2019 - Yescarta is a chimeric antigen receptor T-cell therapy that is custom-made for each patient from his or ...
Posted by Michael Wonder on 15 Feb 2019
CMS proposes coverage with evidence development for chimeric antigen receptor (CAR) T-cell therapy
15 February 2019 - Proposed decision would provide nationwide consistency in CMS’s coverage of the innovative new cancer therapy, to ...
Posted by Michael Wonder on 12 Feb 2019
Yescarta rejected among other SMC decisions
12 February 2019 - Gilead's CAR-T therapy Yescarta (axicabtagene ciloleucel) has been rejected by the Scottish Medicines Consortium (SMC) for ...
Posted by Michael Wonder on 11 Feb 2019
SMC - February 2019 decisions
11 February 2019 - A medicine used to treat a rare blood cancer in children and young adults has today ...
Posted by Michael Wonder on 01 Feb 2019
NICE recommends another revolutionary CAR T-cell therapy for adults with lymphoma
1 February 2019 - Adults with relapsed or refractory diffuse large B-cell lymphoma will be able to access another revolutionary chimeric ...
Posted by Michael Wonder on 21 Jan 2019
Will price be a barrier to new cancer immunotherapy?
19 January 2019 - Advisory group CADTH recommends no funding for new CAR-T therapy until drug company lowers cost. ...
Posted by Michael Wonder on 17 Jan 2019
Gene therapy drug Kymriah should be publicly covered if manufacturer drops price, report recommends
16 January 2019 - A groundbreaking gene therapy for cancer could cost the Canadian health care system more than $400 ...
Posted by Michael Wonder on 15 Jan 2019
Statement from FDA Commissioner and Director of the Center for Biologics Evaluation and Research on new policies to advance development of safe and effective cell and gene therapies
15 January 2019 - The FDA is witnessing a surge of cell and gene therapy products entering early development, evidenced ...
Posted by Michael Wonder on 14 Jan 2019
Rexgenero's lead product REX-001 selected for the EUnetHTA prioritisation list for joint assessments
7 January 2019 - The Prioritisation list consists of just 14 medicinal products that have been identified as being of significant ...
Posted by Michael Wonder on 09 Jan 2019
Biotech proposes paying for pricey drugs by instalment
8 January 2019 - Bluebird Bio develops plan to sell gene-replacement therapy with annual payments contingent on continued effectiveness. ...
Posted by Michael Wonder on 07 Jan 2019
Paying it forward: man pledges $1million to get life-saving cancer treatment in NZ
31 December 2018 - The Herald speaks with Kiwis who have been on the edge of death, had their world ...
Posted by Michael Wonder on 06 Jan 2019
CRISPR Therapeutics and Vertex announce FDA fast track designation for CTX001 for the treatment of sickle cell disease
4 January 2019 - CRISPR Therapeutics and Vertex Pharmaceuticals today announced that the U.S. FDA has granted fast track Designation for ...
Posted by Michael Wonder on 18 Dec 2018
Revolutionary' cancer drug using genetically modified cells approved
19 December 2018 - A revolutionary cancer therapy that supercharges a patient's immune cells to hunt and destroy cancer cells ...